Literature DB >> 14734484

Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP.

Daniel R McCulloch1, Pascal Akl, Hemamali Samaratunga, Adrian C Herington, Dimitri M Odorico.   

Abstract

PURPOSE: The disintegrin metalloprotease ADAM-10 is a multidomain metalloprotease that is potentially significant in tumor progression due to its extracellular matrix-degrading properties. Previously, ADAM-10 mRNA was detected in prostate cancer (PCa) cell lines; however, the presence of ADAM-10 protein and its cellular localization, regulation, and role have yet to be described. We hypothesized that ADAM-10 mRNA and protein may be regulated by growth factors such as 5alpha-dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor, known modulators of PCa cell growth and invasion. EXPERIMENTAL
DESIGN: ADAM-10 expression was analyzed by in situ hybridization and immunohistochemistry in prostate tissues obtained from 23 patients with prostate disease. ADAM-10 regulation was assessed using quantitative reverse transcription-PCR and Western blot analysis in the PCa cell line LNCaP.
RESULTS: ADAM-10 expression was localized to the secretory cells of prostate glands, with additional basal cell expression in benign glands. ADAM-10 protein was predominantly membrane bound in benign glands but showed marked nuclear localization in cancer glands. By Western blot, the 100-kDa proform and the 60-kDa active form of ADAM-10 were synergistically up-regulated in LNCaP cells treated with insulin-like growth factor I plus 5alpha-dihydrotestosterone. Epidermal growth factor also up-regulated both ADAM-10 mRNA and protein.
CONCLUSIONS: This study describes for the first time the expression, regulation, and cellular localization of ADAM-10 protein in PCa. The regulation and membrane localization of ADAM-10 support our hypothesis that ADAM-10 has a role in extracellular matrix maintenance and cell invasion, although the potential role of nuclear ADAM-10 is not yet known.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734484     DOI: 10.1158/1078-0432.ccr-0846-3

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  Proteases and sFlt-1 release in the human placenta.

Authors:  S Zhao; Y Gu; R Fan; L J Groome; D Cooper; Y Wang
Journal:  Placenta       Date:  2010-06       Impact factor: 3.481

2.  Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression.

Authors:  J Zhang; X Qin; Q Sun; H Guo; X Wu; F Xie; Q Xu; M Yan; J Liu; Z Han; W Chen
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

3.  Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells.

Authors:  Neha Kabra Woods; Jaya Padmanabhan
Journal:  J Biol Chem       Date:  2013-09-10       Impact factor: 5.157

4.  ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase.

Authors:  Thomas Tousseyn; Amantha Thathiah; Ellen Jorissen; Tim Raemaekers; Uwe Konietzko; Karina Reiss; Elke Maes; An Snellinx; Lutgarde Serneels; Omar Nyabi; Wim Annaert; Paul Saftig; Dieter Hartmann; Bart De Strooper
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

Review 5.  Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting.

Authors:  Georgina S Butler; Christopher M Overall
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

6.  Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5'-untranslated region.

Authors:  Sven Lammich; Dominik Buell; Sonja Zilow; Ann-Katrin Ludwig; Brigitte Nuscher; Stefan F Lichtenthaler; Claudia Prinzen; Falk Fahrenholz; Christian Haass
Journal:  J Biol Chem       Date:  2010-03-26       Impact factor: 5.157

7.  An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Authors:  L Angenendt; S Reuter; D Kentrup; A S Benk; F Neumann; J Hüve; A C Martens; C Schwöppe; T Kessler; L H Schmidt; T Sauer; C Brand; J-H Mikesch; G Lenz; R M Mesters; C Müller-Tidow; W Hartmann; E Wardelmann; D Neri; W E Berdel; C Roesli; C Schliemann
Journal:  Leukemia       Date:  2017-06-30       Impact factor: 11.528

8.  The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer.

Authors:  Sercan Ergün; Mustafa Ulasli; Yusuf Ziya Igci; Mehri Igci; Sevil Kırkbes; Ersin Borazan; Ahmet Balik; Önder Yumrutaş; Celalettin Camci; Ecir Ali Cakmak; Ahmet Arslan; Serdar Oztuzcu
Journal:  Mol Biol Rep       Date:  2014-10-16       Impact factor: 2.316

9.  Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17.

Authors:  Ga Bin Park; Daejin Kim
Journal:  Mol Cell Biochem       Date:  2017-08-17       Impact factor: 3.396

10.  Versican processing by a disintegrin-like and metalloproteinase domain with thrombospondin-1 repeats proteinases-5 and -15 facilitates myoblast fusion.

Authors:  Nicole Stupka; Christopher Kintakas; Jason D White; Fiona W Fraser; Michael Hanciu; Noriko Aramaki-Hattori; Sheree Martin; Chantal Coles; Fiona Collier; Alister C Ward; Suneel S Apte; Daniel R McCulloch
Journal:  J Biol Chem       Date:  2012-12-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.